Eli Lilly and Company (LLY)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Diabetes/Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 9/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.79% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Can Eli Lilly’s (LLY) Growth Machine Keep Delivering?
- European Union Regulators Recommend Approval For Eli Lilly Weight Loss Pill
- The EU’s Drug Regulator Backed Eli Lilly’s Weight-Loss Pill. Here’s What Foundayo Has to Show on October 29
- What Was Eli Lilly Telling You Before Its Stock Ran?
- Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
- Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
- Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four Months
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Eli Lilly and Company.
Full LLY Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.